Online inquiry

IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6937MR)

This product GTTS-WQ6937MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA), Ankylosing spondylitis (AS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ6937MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ256MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ14826MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ1298MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ10345MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ3756MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ13919MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ767MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ6421MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW